Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib
Authors
Keywords
-
Journal
PLATELETS
Volume 34, Issue 1, Pages -
Publisher
Informa UK Limited
Online
2022-11-04
DOI
10.1080/09537104.2022.2131751
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label study
- (2022) David J. Kuter et al. AMERICAN JOURNAL OF HEMATOLOGY
- Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases
- (2022) Su’an Tang et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: A systematic review and meta-analysis
- (2022) Mathilde Tjepkema et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Understanding vaccine‐induced thrombotic thrombocytopenia (VITT)
- (2022) Caroline Dix et al. INTERNAL MEDICINE JOURNAL
- Neoplasm Risk in Patients With Rheumatoid Arthritis Treated With Fostamatinib: A Systematic Review and Meta-analysis
- (2022) Yuehong Chen et al. Frontiers in Pharmacology
- Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs
- (2022) Maan H. Harbi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice
- (2021) Lin Wang et al. NATURE GENETICS
- The sickening consequences of too much SYK signaling
- (2021) Ivona Aksentijevich NATURE GENETICS
- Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
- (2021) Nina H. Schultz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
- (2021) Andreas Greinacher et al. NEW ENGLAND JOURNAL OF MEDICINE
- High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages
- (2021) Willianne Hoepel et al. Science Translational Medicine
- Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial
- (2021) Nikhil Vergis et al. Trials
- The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity
- (2021) Marcin F Osuchowski et al. Lancet Respiratory Medicine
- Fostamatinib for the treatment of hospitalized adults with COVID-19 A randomized trial
- (2021) Jeffrey R Strich et al. CLINICAL INFECTIOUS DISEASES
- Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
- (2021) Patrícia O. Guimarães et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
- (2021) Vincent C Marconi et al. Lancet Respiratory Medicine
- Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk
- (2021) Amit R. Mehta et al. ACTA HAEMATOLOGICA
- 561. Phase 3 Trial of Fostamatinib for the Treatment of COVID-19: Repurposing an Immunomodulatory Drug Previously Approved for Immune Thrombocytopenia
- (2021) Ziad Mallat et al. Open Forum Infectious Diseases
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China
- (2020) Dawei Wang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Fostamatinib for the treatment of diffuse large B-cell lymphoma.
- (2020) Hendrik-Tobias Arkenau et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting potential drivers of COVID-19: Neutrophil extracellular traps
- (2020) Betsy J. Barnes et al. JOURNAL OF EXPERIMENTAL MEDICINE
- COVID-19 update: Covid-19-associated coagulopathy
- (2020) Richard C. Becker JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Neutrophil Extracellular Traps (NETs) Contribute to Immunothrombosis in COVID-19 Acute Respiratory Distress Syndrome
- (2020) Elizabeth A Middleton et al. BLOOD
- Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia
- (2020) Ralph Boccia et al. BRITISH JOURNAL OF HAEMATOLOGY
- COVID-19-associated coagulopathy: An exploration of mechanisms
- (2020) Meaghan E Colling et al. VASCULAR MEDICINE
- Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention
- (2020) John P. Hussman Frontiers in Pharmacology
- Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19
- (2020) Magdalena Massalska et al. Cells
- Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression
- (2020) Alison R. Walker et al. CLINICAL CANCER RESEARCH
- Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia
- (2020) Adrian Newland et al. Immunotherapy
- Kinase inhibition in autoimmunity and inflammation
- (2020) Ali A. Zarrin et al. NATURE REVIEWS DRUG DISCOVERY
- Recent advance of spleen tyrosine kinase in diseases and drugs
- (2020) Yuxin Shao et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic
- (2020) Jeffrey R Strich et al. JOURNAL OF INFECTIOUS DISEASES
- Cytokine Storm
- (2020) David C. Fajgenbaum et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
- (2020) Andre C. Kalil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thrombosis and Coagulopathy in COVID-19
- (2020) Juan Esteban Gómez-Mesa et al. CURRENT PROBLEMS IN CARDIOLOGY
- Inhibition of spleen tyrosine kinase signaling protects against acute lung injury through blockade of NADPH oxidase and IL-17A in neutrophils and γδ T cells respectively in mice
- (2019) Ahmed Nadeem et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program
- (2019) James B. Bussel et al. AMERICAN JOURNAL OF HEMATOLOGY
- CLEC2 and CLEC5A: Pathogenic Host Factors in Acute Viral Infections
- (2019) Pei-Shan Sung et al. Frontiers in Immunology
- Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials
- (2018) James Bussel et al. AMERICAN JOURNAL OF HEMATOLOGY
- Rheumatoid arthritis
- (2018) Josef S. Smolen et al. Nature Reviews Disease Primers
- Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia
- (2018) Wojciech Jurczak et al. BRITISH JOURNAL OF HAEMATOLOGY
- An emerging role for neutrophil extracellular traps in noninfectious disease
- (2017) Selina K Jorch et al. NATURE MEDICINE
- Heparin-induced thrombocytopenia (HIT)
- (2017) Natalie S Evans et al. VASCULAR MEDICINE
- The Novel Oral Syk Inhibitor, Bl1002494, Protects Mice From Arterial Thrombosis and Thromboinflammatory Brain InfarctionHighlights
- (2016) Judith M.M. van Eeuwijk et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
- (2016) Ian W. Flinn et al. EUROPEAN JOURNAL OF CANCER
- Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials
- (2016) Sumit Kunwar et al. RHEUMATOLOGY INTERNATIONAL
- Neutrophil Extracellular Traps in Pulmonary Diseases: Too Much of a Good Thing?
- (2016) Bárbara Nery Porto et al. Frontiers in Immunology
- An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia
- (2015) J. Sharman et al. BLOOD
- The Syk Inhibitor Fostamatinib Decreases the Severity of Colonic Mucosal Damage in a Rodent Model of Colitis
- (2015) Guray Can et al. Journal of Crohns & Colitis
- Immobilized Immune Complexes Induce Neutrophil Extracellular Trap Release by Human Neutrophil Granulocytes via FcγRIIIB and Mac-1
- (2014) Martina Behnen et al. JOURNAL OF IMMUNOLOGY
- A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor- Antagonist
- (2014) M. C. Genovese et al. JOURNAL OF RHEUMATOLOGY
- Getting Syk: spleen tyrosine kinase as a therapeutic target
- (2014) Robert L. Geahlen TRENDS IN PHARMACOLOGICAL SCIENCES
- Combined In Vivo Depletion of Glycoprotein VI and C-Type Lectin-Like Receptor 2 Severely Compromises Hemostasis and Abrogates Arterial Thrombosis in Mice
- (2013) Markus Bender et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors
- (2012) Rajinder Singh et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Oral Spleen Tyrosine Kinase Inhibitor Fostamatinib Attenuates Inflammation and Atherogenesis in Low-Density Lipoprotein Receptor–Deficient Mice
- (2011) Ingo Hilgendorf et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Critical role for Syk in responses to vascular injury
- (2011) P. Andre et al. BLOOD
- The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies
- (2011) T. LHERMUSIER et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Inhibition of spleen tyrosine kinase suppresses skin and kidney disease in lupus prone mice
- (2010) Guo-Min Deng et al. ARTHRITIS AND RHEUMATISM
- PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model
- (2010) M. P. Reilly et al. BLOOD
- Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database
- (2010) A. Sarpatwari et al. HAEMATOLOGICA
- Therapeutic Targeting of Syk in Autoimmune Diabetes
- (2010) L. Colonna et al. JOURNAL OF IMMUNOLOGY
- Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP)
- (2010) T. B. GERNSHEIMER et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- GPVI and CLEC-2 in hemostasis and vascular integrity
- (2010) S. P. WATSON et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis
- (2010) Michael E. Weinblatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- A Spleen Tyrosine Kinase Inhibitor Reduces the Severity of Established Glomerulonephritis
- (2009) J. Smith et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets
- (2009) J. C. SPALTON et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial
- (2008) Michael E. Weinblatt et al. ARTHRITIS AND RHEUMATISM
- Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk
- (2008) A. Podolanczuk et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation